18 hours ago
1
Cipla Q1 FY26 Results: Mumbai-headquartered pharmaceutical firm Cipla on Friday reported a 10.2 per cent year-on-year rise in consolidated net profit to Rs 1,298 crore for the quarter ended June 30, beating analysts' expectations. Cipla shares spiked immediately after the earnings announcement as the results were announced during the market hours, finishing the day 3.0 per cent stronger at Rs 1,531 apiece on BSE. On NSE, the stock rose 3.2 per cent to settle at Rs 1,535 apiece.
Cipla Q1 Earnings | How did the pharma firm's top-line and bottom-line fare vs estimates?
Cipla logged Rs 6,957 crore in revenue for the June quarter, up 3.9 per cent over the year-ago period, according to a regulatory filing. The top-line also largely met the mark in terms of analyst estimates.
According to Zee Business research, Cipla was expected to report a net profit of Rs 1,174 crore with revenue of Rs 6,970 crore for the quarter.
“I am pleased to share that we continue to make considerable progress across our focused markets," said Umang Vohra, MD and Global CEO, Cipla.
Cipla Q1 | Operational performance
The company's operating profit grew to Rs 1,777 crore from Rs 1,716 crore a year ago, the filing noted.
Its margin remained unchanged at 25.6 per cent as in the year-ago period. Margin is a key measure of a company's profitability.
The drug maker's other income jumped 62 per cent to Rs 259 crore.
Results vs expectations
The results were better than what most analysts had anticipated.
According to Zee Business research, the drug maker was estimated to stage a mixed financial performance with a margin of 23.99 per cent.
The company's North America revenue declined 7 per cent to Rs 1,933 crore, better than a 10 per cent decline that analysts had anticipated.
Cipla shares vs Nifty 50
At the current level, Cipla shares are down about 2.9 per cent on a year-to-date (YTD) basis, in line with a 3.7 per cent decline in the Nifty Pharma but underperforming a 4.6 per cent rise in the Nifty50.
English (US) ·